Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
ORIGINAL SOURCE →via Biopharma Dive
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · energy
- [ENERGY] U.S. Navy Jet Fires Upon, Disables Iranian Tanker Accused of Violating Washington’s Blockade
- [ENERGY] What is everyone misunderstanding about US intelligence report on Iran nuclear threat? - analysis
- [ENERGY] Ukraine hits Russian energy infrastructure to blunt oil revenue surge
- [ENERGY] GTT receives an order from Hudong-Zhonghua Shipbuilding for the tank design of five new LNG Carriers
- [ENERGY] Statement from CEO Dr. Noel Hacegaba on Oil Tanker New Corolla
- [ENERGY] Gold in the Shadow of Oil Price Shock - Investing.com